Chronic vegetative states and apallic syndrome

Types of patients: The patients with the disease of the damaged brain who have not recovered consciousness after critical condition: all patients with severe post-traumatic, post-hypoxic and post-ischemic organic damages of the central nervous system, post-resuscitation disease and chronic vegetative conditions (apallic syndrome, akinetic mutism, locked-in syndrome, diffuse axonal asinopsia, etc.).

Therapy principle: The method of radioneurobioengineering has been developed and implemented in the clinical practice. This is an innovative patented method of remote multiwave non-contact bioengineering of the human brain and spinal cord for patients with organic damage of the central nervous system (CNS). The treatment aims to restore the damaged nervous tissue of the brain and spinal cord, and involves the use of modern biomedical technologies of personalised medicine in a specific bioengineering algorithm and approved computerized biotherapy methods based on various types of electromagnetic radiation. The method employs different types of electromagnetic radiation: ionizing radiation, focused ultrasound, structural resonance effect, electrical stimulation of muscles and nerves of the extremities and transcranial magnetostimulation. In addition, therapy and other physiotherapeutic and pharmaceutical medical technologies approved for clinical use are used to restore damaged nervous tissue. All stages of radioneurobioengineering plastics are performed on standard medical equipment according to the bioengineering algorithm for the reconstruction of the brain and spinal cord. All therapeutic methods are approved for clinical use by the Ministry of Health of Russia.

Results: the method allows for partial restoration of the lost functions of the central nervous system and, in terms of effectiveness, is alternative to reconstructive and restorative neurosurgical operations on the human brain and spinal cord. Efficiency in the treatment of chronic vegetative states depends on the initial cause of the disease and varies from 35 to 66.7% when the patient is included in the protocol no later than 12 months after the onset of the condition.